Clinical Trials Logo

Clinical Trial Summary

The investigators' recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine addicted persons. The investigators will attempt to augment this effect by a) doubling the number of propranolol-medicated cocaine cue exposure (CCE) retrieval sessions and b) increasing the dose of propranolol. It is expected that propranolol treated groups, relative to placebo treated groups, will evidence greater reduction of craving, cue reactivity and cocaine use during follow-up cocaine cue exposures. Also, these effects will be greater for those who receive 80mg of propranolol as opposed to 40mg.


Clinical Trial Description

Three groups of CD (cocaine dependant) participants will receive two sessions of cocaine cue exposure (CCE), each separated by a 24 hr. period and both conducted while the participants remain in hospital. One group (PBO) will receive placebo following each CCE session while the second (40PP) and third (80PP) group will receive 40 mg and 80 mg propranolol, respectively. Participants will return two days, and 1, 3, and 6 weeks after discharge and will be administered a CCE session to assess for maintenance/generalization of disruption of reconsolidation (DoR) effects on craving and cue reactivity to familiar and novel cocaine cues. Participants will also be assessed 3 times weekly for cocaine use (self-report & urine drug screen) during follow-up. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01822587
Study type Interventional
Source Medical University of South Carolina
Contact
Status Completed
Phase Phase 2
Start date September 2013
Completion date November 5, 2018

See also
  Status Clinical Trial Phase
Completed NCT04336293 - sTMS for Substance Use-disordered Veterans N/A
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT01601743 - Exercise as a Behavioral Treatment for Cocaine Dependence N/A
Completed NCT02563769 - Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study Phase 1
Completed NCT01651377 - Pramipexole as a Treatment for Cocaine Dependence Phase 1
Completed NCT02768441 - Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots Early Phase 1
Completed NCT02626494 - Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Phase 4
Recruiting NCT02892851 - Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction. N/A
Not yet recruiting NCT01319214 - Reducing Drug Craving Memories N/A
Recruiting NCT01259362 - Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients Phase 2
Completed NCT01211418 - Integrative Meditation (IM) for Cocaine Addiction N/A
Recruiting NCT03423667 - Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction Phase 2
Completed NCT01984177 - Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence N/A
Completed NCT01887366 - Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects Phase 2
Completed NCT01337297 - Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction Phase 1/Phase 2
Completed NCT01067846 - Cognitive Enhancement and Relapse Prevention in Cocaine Addiction N/A
Completed NCT01651364 - A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence Phase 1
Recruiting NCT03018236 - Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Phase 4
Completed NCT01929343 - Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Phase 2
Completed NCT01281202 - Vigabatrin for the Treatment of Cocaine Dependency Phase 2/Phase 3